Eikon Therapeutics, Inc. (EIKN)
NASDAQ: EIKN · Real-Time Price · USD
8.71
+0.15 (1.75%)
Apr 29, 2026, 11:41 AM EDT - Market open
Eikon Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Net Income | -324.25 | -243.81 | -242 |
| Depreciation & Amortization | 24.18 | 25.39 | 17.75 |
| Asset Writedown & Restructuring Costs | 21.23 | - | 35 |
| Loss (Gain) From Sale of Investments | -5.54 | -9.46 | -21.11 |
| Stock-Based Compensation | 18.04 | 12.43 | 9.54 |
| Change in Accounts Payable | -3.81 | 2.95 | 0.24 |
| Change in Other Net Operating Assets | 81.65 | 77.7 | 9.74 |
| Operating Cash Flow | -188.52 | -134.8 | -190.85 |
| Capital Expenditures | -46.74 | -84.8 | -28.51 |
| Investment in Securities | -134.6 | 236.15 | 165.46 |
| Investing Cash Flow | -181.34 | 151.35 | 136.95 |
| Issuance of Common Stock | 1.9 | 0.24 | 0.4 |
| Financing Cash Flow | 352.05 | 0.24 | 105.81 |
| Net Cash Flow | -17.81 | 16.8 | 51.91 |
| Free Cash Flow | -235.26 | -219.6 | -219.36 |
| Free Cash Flow Per Share | -81.29 | -87.16 | -108.26 |
| Cash Interest Paid | 0.89 | 0.03 | 0.04 |
| Levered Free Cash Flow | -208.89 | -190.73 | - |
| Unlevered Free Cash Flow | -208.37 | -190.71 | - |
| Change in Working Capital | 77.84 | 80.65 | 9.98 |
Source: S&P Capital IQ. Standard template.
Financial Sources.